Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qol Holdings Co's EBIT per Share for the
three
months ended in Mar. 2026 was 円136.14.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円392.80.
During the past 12 months, the average EBIT per Share Growth Rate of Qol Holdings Co was 9.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 15.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 12.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 6.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Qol Holdings Co's EBIT per Share or its related term are showing as below:
TSE:3034'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -15.6 Med: 10.3 Max: 56.8
Current: 15.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Qol Holdings Co was 56.80% per year. The lowest was -15.60% per year. And the median was 10.30% per year.
TSE:3034's 3-Year EBIT Growth Rate is ranked better than 54.58% of 524
companies
in the Healthcare Providers & Services industry
Industry Median: 11.95
vs TSE:3034: 15.40
Qol Holdings Co's EBIT for the
three
months ended in Mar. 2026 was 円5,111 Mil.
Qol Holdings Co (TSE:3034) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Qol Holdings Co EBIT per Share Related Terms
Qol Holdings Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for Qol Holdings Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円392.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qol Holdings Co (TSE:3034) has a EBIT per Share of 円392.80 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Qol Holdings Co and its competitors. According to the industry distribution chart, Qol Holdings Co ranks #238 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 45.4%.
Is Qol Holdings Co's EBIT per Share too high?
Qol Holdings Co's current EBIT per Share is 円392.80. Based on the distribution chart, Qol Holdings Co ranks #238 out of 524 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Qol Holdings Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Qol Holdings Co's EBIT per Share compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Qol Holdings Co ranks #238 out of 524 companies for EBIT per Share. This puts Qol Holdings Co in the upper half of its industry. The industry median EBIT per Share is 11.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.95, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Qol Holdings Co and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qol Holdings Co's current EBIT per Share is 円392.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qol Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Qol Holdings Co (TSE:3034) is currently considered Fairly Valued. The stock's GF Value™ is 円2,284.45, compared to a current price of 円2,082.00 — trading 8.9% below its estimated fair value. The current EBIT per Share is 円392.80. Qol Holdings Co's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Qol Holdings Co (TSE:3034), the current EBIT per Share is 円392.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qol Holdings Co (TSE:3034) Overvalued in 2026?
Based on GuruFocus' analysis, Qol Holdings Co stock appears to be undervalued.
The current stock price of 円2,082.00 is trading 8.9% below its estimated GF Value™ of 円2,284.45.
GuruFocus considers Qol Holdings Co to be Fairly Valued.
Key valuation signals for TSE:3034:
EBIT per Share: 円392.80
GF Value™: 円2,284.45 vs. price of 円2,082.00 (8.9% below fair value)
No single metric tells the full story. See the TSE:3034 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qol Holdings Co Ltd provides pharmacy services under health insurance and sells pharmaceutical products. Its mission is to create healthy and comfortable living environments for everybody in those communities. The company operates through: Pharmacy and BPO segments. Under the Pharmacy segment the company puts customers first in-store development strategy, which is based on building one-on-one relationships with drug-prescribing clinics and hospitals in order to get the pharmacy services that include medical information. The BPO contracting segment includes clinical trials and projects and develops pamphlets and websites for medical institutions to promote sales of pharmaceutical products and provide advice on proper pharmaceutical product.
88GF Score
Get the complete analysis for TSE:3034
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3034 has been successfully added to your 
